Goldman Sachs Group Inc Akero Therapeutics, Inc. Transaction History

Goldman Sachs Group Inc

  • $605 Billion
  • Q3 2024

A detailed history of Goldman Sachs Group Inc transactions in Akero Therapeutics, Inc. stock. As of the latest transaction made, Goldman Sachs Group Inc holds 662,321 shares of AKRO stock, worth $35.8 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares
662,321
Previous 782,950 15.41%
Holding current value
$35.8 Million
Previous $18.4 Million 3.45%
% of portfolio
0.0%
Previous 0.0%

Shares

19 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024
SELL
$21.45 - $29.34 $2.59 Million - $3.54 Million
-120,629 Reduced 15.41%
662,321 $19 Million
Q2 2024

Aug 13, 2024
BUY
$18.31 - $24.62 $3.54 Million - $4.75 Million
193,098 Added 32.74%
782,950 $18.4 Million
Q1 2024

May 15, 2024
SELL
$17.76 - $31.18 $415,992 - $730,329
-23,423 Reduced 3.82%
589,852 $14.9 Million
Q4 2023

Feb 13, 2024
BUY
$11.38 - $50.33 $3.21 Million - $14.2 Million
282,190 Added 85.23%
613,275 $14.3 Million
Q3 2023

May 14, 2024
SELL
$41.19 - $52.25 $11.6 Million - $14.7 Million
-282,190 Reduced 46.01%
331,085 $16.7 Million
Q3 2023

Nov 14, 2023
BUY
$41.19 - $52.25 $5.03 Million - $6.38 Million
122,042 Added 58.38%
331,085 $16.7 Million
Q2 2023

May 14, 2024
SELL
$36.89 - $56.88 $525,608 - $810,426
-14,248 Reduced 6.38%
209,043 $9.76 Million
Q2 2023

Aug 14, 2023
SELL
$36.89 - $56.88 $525,608 - $810,426
-14,248 Reduced 6.38%
209,043 $9.76 Million
Q1 2023

May 14, 2024
BUY
$37.27 - $50.24 $1.39 Million - $1.88 Million
37,379 Added 20.11%
223,291 $8.54 Million
Q1 2023

May 11, 2023
BUY
$37.27 - $50.24 $1.39 Million - $1.88 Million
37,379 Added 20.11%
223,291 $8.54 Million
Q4 2022

May 14, 2024
SELL
$33.44 - $54.8 $64.6 Million - $106 Million
-1,932,885 Reduced 91.23%
185,912 $10.2 Million
Q4 2022

Feb 13, 2023
SELL
$33.44 - $54.8 $64.6 Million - $106 Million
-1,932,885 Reduced 91.23%
185,912 $10.2 Million
Q3 2022

May 14, 2024
BUY
$10.15 - $34.05 $2.59 Million - $8.69 Million
255,193 Added 13.69%
2,118,797 $72.1 Million
Q3 2022

Nov 10, 2022
BUY
$10.15 - $34.05 $2.59 Million - $8.69 Million
255,193 Added 13.69%
2,118,797 $72.1 Million
Q2 2022

May 14, 2024
BUY
$8.0 - $15.01 $10 Million - $18.8 Million
1,250,329 Added 203.88%
1,863,604 $0
Q2 2022

Aug 15, 2022
BUY
$8.0 - $15.01 $6.17 Million - $11.6 Million
770,924 Added 70.55%
1,863,604 $17.6 Million
Q1 2022

May 16, 2022
SELL
$12.97 - $22.26 $8.74 Million - $15 Million
-674,034 Reduced 38.15%
1,092,680 $15.5 Million
Q4 2021

Feb 14, 2022
BUY
$19.87 - $26.24 $34.5 Million - $45.5 Million
1,735,530 Added 5565.45%
1,766,714 $37.4 Million
Q3 2021

Nov 10, 2021
BUY
$18.65 - $25.46 $581,581 - $793,944
31,184 New
31,184 $697,000

Others Institutions Holding AKRO

# of Institutions
190
Shares Held
74.6M
Call Options Held
241K
Put Options Held
647K
View Full List

About Akero Therapeutics, Inc.

AKRO Quotes by TradingView
  • Ticker AKRO
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 46,417,600
  • Market Cap $2.51B
  • Description
  • Akero Therapeutics, Inc., a cardio-metabolic nonalcoholic steatohepatitis (NASH) company, engages in the development of medicines designed to restore metabolic balance and improve overall health. The company's lead product candidate is efruxifermin (EFX), an analog of fibroblast growth factor 21, which protects against cellular stress and regula...
More about AKRO
Track This Portfolio

Track Goldman Sachs Group Inc Portfolio

Follow Goldman Sachs Group Inc and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Goldman Sachs Group Inc, based on Form 13F filings with the SEC.

News

Stay updated on Goldman Sachs Group Inc with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email